A Phase 1a/1b Study to Investigate the Safety, Tolerability, Microbiological Response, and Pharmacokinetics of Inhaled Rev-56 in Adult Healthy Volunteers and Adult Non-cystic Fibrosis Bronchiectasis (NCFB) Patients With Chronic P. Aeruginosa

Conditions : Healthy Participants; Non-cystic Fibrosis Bronchiectasis Interventions : Combination Product: Rev-56 for Inhalation; Drug: Placebo: Normal saline Sponsors : Revagenix, Inc.; National…